암 바이오마커 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 생체분자별, 용도별, 기술별, 지역별 및 부문별 예측(2026-2033년)

Cancer Biomarkers Market Summary

The global cancer biomarkers market size was valued at USD 26.92 billion in 2025 and is projected to reach USD 65.30 billion by 2033, growing at a CAGR of 11.82% from 2026 to 2033. The growth is attributed to rising cancer cases and the increasing focus on early diagnosis and personalized treatment.

Advancements in genomics, proteomics, next-generation sequencing, and molecular diagnostic technologies are accelerating innovation in the cancer biomarker testing market. Hospitals and labs are adopting biomarker-based tests to improve outcomes. Supportive government initiatives and expanding research activities further boost growth, while demand for targeted therapies continues to create new opportunities worldwide.

Cancer remains one of the leading global health challenges and a major cause of mortality in the 21st century. According to a study published in The Lancet in September 2025, findings from the Global Burden of Disease (GBD) 2023 study indicate that cancer burden was assessed across 47 cancer types in 204 countries and territories from 1990 to 2023, with projections extending to 2050. Cancer was estimated to be the second leading cause of death globally in 2023, after cardiovascular diseases, with total cancer-related deaths expected to exceed 18 million by 2050. Furthermore, estimates published by the Institute for Health Metrics and Evaluation in September 2025 indicate that there were 18.5 million new cancer cases and more than 10.4 million deaths globally, contributing to approximately 271 million disability-adjusted life years (DALYs) lost. Of these, nearly 60% of cancer cases and over 60% of cancer deaths occurred in low- and middle-income countries, highlighting significant disparities in disease burden and access to care. Lung cancer and colorectal cancer were identified as the leading and second-leading causes of cancer-related deaths in 2023, respectively. The increasing number of patients requiring ongoing care is expected to accelerate the adoption of biomarker-based technologies, thereby supporting the growth of the cancer biomarkers market.

Research plays a critical role in advancing the cancer biomarkers market by supporting the development of innovative technologies for early diagnosis, targeted therapy selection, and disease monitoring. Increasing government funding continues to accelerate oncology research and biomarker discovery initiatives. The National Cancer Institute (NCI) remains a major contributor, supporting research activities across its headquarters in Maryland, academic institutions, and global collaborations. According to data published by the NCI in July 2025, the institute's funds totaled USD 7.2 billion, with 43.3% of the obligated budget allocated to Research Project Grants. These investments are significantly advancing biomarker-based diagnostics, precision oncology, immuno-oncology, and liquid biopsy technologies, thereby supporting innovation and growth in the cancer biomarkers market.

Technological advancements are transforming the cancer biomarkers market by improving precision oncology, early detection, and personalized treatment selection. Increasing integration of biomarker-driven diagnostics with targeted therapies continues to expand clinical applications. For instance, in January 2025, Roche received FDA approval for its PATHWAY HER2 (4B5) companion diagnostic test for identifying patients with HER2-ultralow metastatic breast cancer, highlighting advancements in biomarker-based patient stratification. Continuous innovation in liquid biopsy technologies is also accelerating market growth. In June 2024, Guardant Health expanded the clinical application of its Guardant360 liquid biopsy test for comprehensive genomic profiling and real-time tumor monitoring. Furthermore, in August 2024, Illumina advanced its oncology sequencing platforms, supporting high-throughput genomic profiling and strengthening biomarker-based precision oncology applications across multiple cancer types.

Global Cancer Biomarkers Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cancer biomarkers market report based on type, biomolecule, application, technology, and region

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Cervical Cancer
• Liver Cancer
• Lung Cancer
• Others
• Biomolecule Outlook (Revenue, USD Million, 2021 - 2033)
• Genetic Biomarkers
• Epigenetic Biomarkers
• Metabolic Biomarkers
• Proteomic Biomarkers
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Drug Discovery and Development
• Diagnostics
• Personalized Medicine
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Polymerase Chain Reaction (PCR)-based Technologies
• Next-Generation Sequencing (NGS)-based Technologies
• Immunoassay-based Technologies
• In Situ Hybridization (ISH) & Cytogenetic Technologies
• Mass Spectrometry-based Technologies
• Imaging-based Biomarker Technologies
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Biomolecule
  • 1.2.3. Application
  • 1.2.4. Technology
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Cancer Biomarker Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing Prevalence of Cancer
    • 3.2.1.2. Increasing Government Funding for Cancer Research
    • 3.2.1.3. Technological Advancement
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Reimbursement Policies
    • 3.2.2.2. Large Capital Investment
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Cancer Biomarker Market: Type Business Analysis

• 4.1. Type Market Share, 2025 & 2033
• 4.2. Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 4.4. Breast Cancer
  • 4.4.1. Breast Cancer Market, 2021 - 2033 (USD Million)
• 4.5. Prostate Cancer
  • 4.5.1. Prostate Cancer Market, 2021 - 2033 (USD Million)
• 4.6. Colorectal Cancer
  • 4.6.1. Colorectal Cancer Market, 2021 - 2033 (USD Million)
• 4.7. Cervical Cancer
  • 4.7.1. Cervical Cancer Market, 2021 - 2033 (USD Million)
• 4.8. Liver Cancer
  • 4.8.1. Liver Cancer Market, 2021 - 2033 (USD Million)
• 4.9. Lung Cancer
  • 4.9.1. Lung Cancer Market, 2021 - 2033 (USD Million)
• 4.10. Others
  • 4.10.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Cancer Biomarker Market: Biomolecule Business Analysis

• 5.1. Biomolecule Market Share, 2025 & 2033
• 5.2. Biomolecule Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Biomolecule, 2021 to 2033 (USD Million)
• 5.4. Genetic Biomarkers
  • 5.4.1. Genetic Biomarkers Market, 2021 - 2033 (USD Million)
• 5.5. Epigenetic Biomarkers
  • 5.5.1. Epigenetic Biomarkers Market, 2021 - 2033 (USD Million)
• 5.6. Metabolic Biomarkers
  • 5.6.1. Metabolic Biomarkers Market, 2021 - 2033 (USD Million)
• 5.7. Proteomic Biomarkers
  • 5.7.1. Proteomic Biomarkers Market, 2021 - 2033 (USD Million)

Chapter 6. Cancer Biomarker Market: Application Business Analysis

• 6.1. Application Market Share, 2025 & 2033
• 6.2. Application Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 6.4. Drug Discovery and Development
  • 6.4.1. Drug Discovery and Development Market, 2021 - 2033 (USD Million)
• 6.5. Diagnostics
  • 6.5.1. Diagnostics Market, 2021 - 2033 (USD Million)
• 6.6. Personalized Medicine
  • 6.6.1. Personalized Medicine Market, 2021 - 2033 (USD Million)

Chapter 7. Cancer Biomarker Market: Technology Business Analysis

• 7.1. Technology Market Share, 2025 & 2033
• 7.2. Technology Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Technology, 2021 to 2033 (USD Million)
• 7.4. Polymerase Chain Reaction (PCR)-based Technologies
  • 7.4.1. Polymerase Chain Reaction (PCR)-based Technologies Market, 2021 - 2033 (USD Million)
• 7.5. Next-Generation Sequencing (NGS)-based Technologies
  • 7.5.1. Next-Generation Sequencing (NGS)-based Technologies Market, 2021 - 2033 (USD Million)
• 7.6. Immunoassay-based Technologies
  • 7.6.1. Immunoassay-based Technologies Market, 2021 - 2033 (USD Million)
• 7.7. In Situ Hybridization (ISH) & Cytogenetic Technologies
  • 7.7.1. In Situ Hybridization (ISH) & Cytogenetic Technologies Market, 2021 - 2033 (USD Million)
• 7.8. Mass Spectrometry-based Technologies
  • 7.8.1. Mass Spectrometry-based Technologies Market, 2021 - 2033 (USD Million)
• 7.9. Imaging-based Biomarker Technologies
  • 7.9.1. Imaging-based Biomarker Technologies Market, 2021 - 2033 (USD Million)

Chapter 8. Cancer Biomarker Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2025 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 8.4. North America
  • 8.4.1. North America Cancer Biomarker Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Framework
    • 8.4.2.5. U.S. Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Framework
    • 8.4.3.5. Canada Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Framework
    • 8.4.4.5. Mexico Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Framework
    • 8.5.2.5. UK Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Framework
    • 8.5.3.5. Germany Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Reimbursement Framework
    • 8.5.4.5. France Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Target Disease Prevalence
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Reimbursement Framework
    • 8.5.5.5. Italy Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Target Disease Prevalence
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Reimbursement Framework
    • 8.5.6.5. Spain Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Target Disease Prevalence
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Reimbursement Framework
    • 8.5.7.5. Denmark Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Target Disease Prevalence
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Reimbursement Framework
    • 8.5.8.5. Sweden Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Target Disease Prevalence
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Reimbursement Framework
    • 8.5.9.5. Norway Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Framework
    • 8.6.2.5. Japan Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Framework
    • 8.6.3.5. China Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Framework
    • 8.6.4.5. India Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Framework
    • 8.6.5.5. Australia Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Target Disease Prevalence
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Reimbursement Framework
    • 8.6.6.5. South Korea Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Target Disease Prevalence
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Reimbursement Framework
    • 8.6.7.5. Thailand Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Target Disease Prevalence
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Reimbursement Framework
    • 8.7.2.5. Brazil Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Target Disease Prevalence
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Reimbursement Framework
    • 8.7.3.5. Argentina Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.8. Middle East and Africa
  • 8.8.1. Middle East and Africa Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Target Disease Prevalence
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Reimbursement Framework
    • 8.8.2.5. South Africa Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Target Disease Prevalence
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Reimbursement Framework
    • 8.8.3.5. Saudi Arabia Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Target Disease Prevalence
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Reimbursement Framework
    • 8.8.4.5. UAE Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Target Disease Prevalence
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Reimbursement Framework
    • 8.8.5.5. Kuwait Cancer Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Abbott
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. QIAGEN
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Thermo Fisher Scientific Inc.
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Illumina, Inc.
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Agilent Technologies, Inc.
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. F. Hoffmann-La Roche Ltd.
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Merck & Co. Inc.
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. Hologic, Inc.
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Sino Biological Inc.
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives